Ferulic acid carbamate derivatives represent a novel class of dual-targeting therapeutics for Alzheimer's disease (AD) that simultaneously inhibit butyrylcholinesterase (BuChE) and activate the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway. This approach addresses two key pathological hallmarks of AD: cholinergic deficit and oxidative stress.
The lead compounds from this series, particularly 5c, 5g, and 5h, demonstrate exceptional BuChE selectivity (>150-fold over acetylcholinesterase/AChE), neuroprotective effects against oxidative damage and amyloid-beta toxicity, and in vivo efficacy in transgenic AD models[1].
Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a natural phenolic compound found in various plant sources including wheat, rice, oats, and fruits. It exhibits well-documented neuroprotective properties:
However, ferulic acid's clinical translation has been limited by its poor blood-brain barrier (BBB) permeability and rapid metabolism. The carbamate derivative approach addresses these pharmacokinetic limitations while enhancing target engagement.
The carbamate derivative strategy involves conjugating ferulic acid with carbamate moieties to improve:
Key findings from the SAR studies include[2]:
BuChE (also known as pseudocholinesterase or pseudo-acetylcholinesterase) is increasingly recognized as a therapeutically important target in AD[3]:
Carbamate derivatives inhibit BuChE through a reversible carbamylation mechanism:
The >150-fold selectivity for BuChE over AChE observed in compounds 5c and 5e is particularly valuable because:
The Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway is the master regulator of cellular antioxidant response[4]:
In AD, the Nrf2 pathway is dysfunctional, leading to inadequate antioxidant responses against oxidative stress from Aβ toxicity, mitochondrial dysfunction, and neuroinflammation.
The ferulic acid carbamate derivatives activate Nrf2 through Keap1-Nrf2 dissociation[2:1]:
In vitro studies showed that compounds 5c, 5g, and 5h:
In HT22 hippocampal neurons, the lead compounds demonstrated[2:2]:
| Compound | BuChE IC₅₀ (nM) | AChE IC₅₀ (nM) | BuChE Selectivity | Nrf2 Activation |
|---|---|---|---|---|
| 5c | 15.2 | >2300 | >150-fold | +++ |
| 5e | 18.7 | >2800 | >150-fold | ++ |
| 5g | 22.4 | 1850 | ~83-fold | +++ |
| 5h | 28.1 | 2100 | ~75-fold | +++ |
In Aβ transgenic C. elegans models, lead compounds demonstrated:
Computational studies confirmed that compound 5c:
The ferulic acid carbamate derivatives offer several unique advantages:
| Feature | Donepezil/Rivastigmine | Ferulic Acid Carbamates |
|---|---|---|
| Primary target | AChE (+ weak BuChE) | BuChE (selective) |
| Antioxidant | No | Yes (via Nrf2) |
| Selectivity | AChE > BuChE | BuChE > AChE |
| BBB penetration | Moderate | Optimized |
Given the strong preclinical data:
Liu L, Wu C, Chen D, Chen Y, Huang G. Ferulic acid: a comprehensive review of its pharmacology, pharmacokinetics, and therapeutic potential in neurodegenerative diseases. Current Neuropharmacology. 2019. ↩︎
Lao K, Li Y, Xiao Y, Sun Y, Dai Y, Li H, Yang Y, Zhang Y, Wang J, Li W, Gou X, Guan L. Discovery of ferulic acid carbamate derivatives as dual-targeting agents of BuChE and Nrf2 for Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2026. ↩︎ ↩︎ ↩︎
Kumar S, Singh S, Singh M. Butyrylcholinesterase: structure, function, and therapeutic targeting in Alzheimer's disease. Neurochemistry International. 2020. ↩︎
Sandberg A, Nordberg A. The Nrf2-ARE pathway as a therapeutic target in Alzheimer's disease. Free Radical Biology and Medicine. 2021. ↩︎